ADA 2021 | SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes | diabetes.medicinematters.com

Register Login

Medicine Matters Diabetes

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

06-28-2021 | ADA 2021 | Conference coverage | Video

SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide (5:44).

Related content

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-1: Tirzepatide has ‘potent’ glucose-lowering and weight loss efficacy

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-3: Tirzepatide proves better option than degludec for type 2 diabetes

06-27-2021 | ADA 2021 | Conference coverage | News

SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-dependent type 2 diabetes

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Phase 3 trials of tirzepatide in type 2 diabetes and obesity

Version: 0.2067.0